Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion  

作　　者：Cun-Liang Cai Ming-Qiang Zhang Jun Guo Li-Wan Wang Jing-Quan Zhao Wen-Jia Guo Xiang-Dong Mu 

机构地区：[1]Department of Respiratory and Critical Care Medicine,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing 102218,China

出　　处：《Chinese Medical Journal》2019年第24期3003-3005,共3页中华医学杂志（英文版）

摘　　要：To the Editor:Spindle cell carcinoma(SpCC)is a rare histological type of sarcomatoid carcinoma consisting of spindle-shaped tumor cells.SpCC can occur in many different organs,including the lungs.There is limited data on the clinical presentation,genetic mutant phenotype,treatment,and outcome of lung SpCC.The efficacy of molecular targeted therapy for this tumor is still unclear.[1]Here,we report an adult male with metastatic SpCC harboring a Tropomyosin 3-ROS proto-oncogene 1(TPM3-ROS1)fusion who showed a long-term response to targeted therapy by crizotinib,a tyrosine kinase inhibitor(TKI).

关 键 词：METASTATIC LUNG ORGANS 

分 类 号：R73[医药卫生—肿瘤]